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Notes from the Field
Hospital Contact Investigation for a Patient Who 
Developed a Zoster Vaccine–Related Rash — 
Maryland, February 2015
Diana P. Le, MD1; Jamie Vega, DO2; Lucas A Johnson, MD1
On January 30, 2015, the public health department of a 
Maryland hospital was notified of a patient who developed 
a disseminated rash after receiving the live attenuated zoster 
vaccine, Zostavax (Merck). Zostavax is routinely provided 
to adults aged ≥50 years for the prevention of herpes zoster 
(shingles). The patient, a man aged 51 years, was evaluated 
in an outpatient clinic on postvaccination day 21, at which 
time physical exam revealed a nonpainful, nonpruritic, mixed 
maculopapular and vesicular rash (approximately 50 total 
lesions) involving the patient’s face, torso, groin, and arms. 
The patient was born and raised in Greece and reported that 
he did not have varicella (chickenpox) as a child, and he did 
not recall previous vaccination against varicella. For 10 months 
before developing the rash, the patient received a weekly 
10-mg dose of methotrexate for rheumatoid factor-negative 
spondyloarthropahy. He reported no contact with persons 
known or suspected to have active varicella or zoster and had 
no cough or other constitutional symptoms. Valacyclovir, an 
oral antiviral medication, was prescribed, and the patient was 
instructed to remain at home and avoid outside contacts until 
the lesions crusted over. All household contacts of the patient 
had documented evidence of receipt of 2 doses of varicella 
vaccine. Direct immunofluorescence testing and culture of 
vesicular fluid were positive for varicella zoster virus (VZV) 
on postvaccination day 24.
Although zoster is less contagious than varicella (particularly 
if the rash is appropriately covered), the unusual presentation 
of the rash raised concerns for varicella. A contact investiga-
tion was initiated by the hospital’s public health department 
to identify health care worker contacts as well as clinic waiting 
room patient contacts who might have been exposed to the 
patient during the outpatient clinic visit. Eight health care 
workers were identified as having had face-to-face contact with 
the patient; all had documented evidence of VZV immunity 
by antibody titer or documentation of receipt of 2 doses of 
varicella vaccine. The patient spent approximately 25 minutes 
in the clinic waiting room, resulting in potential exposure of 
18 persons. Among these persons, 15 had evidence of VZV 
immunity and the three who did not were offered vaccination. 
None of the unimmunized waiting room contacts was preg-
nant, had an immunocompromising medical condition, or was 
undergoing immunomodulatory treatment. In accordance with 
current guidelines, exposed health care workers were instructed 
to remain vigilant for signs or symptoms of varicella (i.e., fever, 
headache, or other constitutional symptoms and skin lesions) 
for 21 days after exposure and to immediately report symptoms 
to the hospital’s public health department if any occurred (1). 
No cases of varicella were identified in potentially exposed 
patients or health care workers after 21 days of surveillance. 
After the conclusion of the contact investigation, vesicular fluid 
collected and sent for genotyping at time of the initial patient 
evaluation demonstrated vaccine-type (Oka/Merck) virus.
Development of a generalized rash following zoster vaccina-
tion is rare, but can occur. Circulation of wild type VZV has 
declined considerably during the era of varicella and zoster 
vaccines (2); however, given the delays and challenges in 
determining if a vesicular rash in a vaccine recipient is VZV, 
early institution of a contact investigation by clinicians and 
public health officials might mitigate the risk for VZV trans-
mission. Potentially exposed contacts without evidence of 
VZV immunity should be vaccinated against varicella. Both 
varicella vaccination and varicella zoster immune globulin are 
most effective in preventing disease in susceptible persons when 
administered as soon as possible after exposure (3).
Health care settings should ensure that health care workers 
are immune to VZV. Documentation of immunity includes: 
1) written documentation of vaccination with 2 doses of vari-
cella vaccine; 2) laboratory evidence of immunity or laboratory 
confirmation of disease; 3) diagnosis or verification of a history 
of varicella disease by a health care provider; or 4) diagnosis 
or verification of a history of herpes zoster by a health care 
provider (4,5). This case highlights the importance of main-
taining vigilance for unusual events following the use of live 
vaccines in persons who receive immunosuppressant medica-
tions, the importance of vaccination for primary prevention 
of communicable diseases in hospital settings, and the value of 
a robust occupational health program as a critical component 
of hospital infection control efforts.
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